BioPharma Today

Register for the New York Pharma Forum

Register for the New York Pharma Forum Summer Social aboard the Intrepid with CEOs sharing their business wish lists ...

Latest News From "The Pink Sheet" DAILY - Celgene And Sanofi In Oncology Deals

Celgene is planning an aggressive development and marketing push for the chemotherapeutic Abraxane, a novel nanometer-sized formulation of paclitaxel, with the aim of driving the drug's sales to $1 billion by 2015 after acquiring Abraxane developer Abraxis Biosciences.

Latest News From "The Pink Sheet" DAILY - Lilly Signs Marcadia As Partner

Lilly Partners With Marcadia For Injectable Pens To Treat Hypoglycemia

Already a leader in emergency kits, Lilly will support trials on a simpler device that doesn't require complex preparation.   read more

Coming In Wednesday's "The Pink Sheet" DAILY

Abbott is planning to divest the flu vaccine unit it acquired last year in its $6.6 billion purchase of Solvay’s pharmaceuticals business. Reportedly, the drug maker circulated marketing materials on the unit to a number of large health care companies last week, presumably including Big Pharma companies with a larger base in vaccines, such as GlaxoSmithKline and AstraZeneca.

Merck: Poised to be THE biosimilars pioneer

Find out how they’ll do it and what it means for the rest of the industry in this FREE article just published in “The Pink Sheet” DAILY:
Merck Prepares To Test Drive Biosimilar Pathway In The U.S.

DOWNLOAD FREE HERE: http://www.elsevierbi.com/mktg/HTML/pdwtl610.html

Latest News From "The Pink Sheet" DAILY - Merck Plans To Use Biosimilar Path In The U.S.

Merck Prepares To Test Drive Biosimilar Pathway In The U.S.

Since the passage of healthcare reform legislation, many in the industry have questioned the viability of the biosimilar pathway, but Merck is ready to put it to the test.   read more

Coming In Tuesday's "The Pink Sheet" DAILY - Supreme Court Rejects Narrow Test Of What Is A Patentable Process

To the relief of the biotech industry, the Supreme Court rejected the Federal Circuit's narrow test of whether a process is eligible to be patented. In Bilski v. Kappos, the court ruled that a process need not be tied to a machine or apparatus or transform an article to be patentable. 

FT China Healthcare and Life Sciences Summit

As governments around the world grapple with the challenge of reforming their ailing healthcare systems, China has moved faster and further than most...

Latest News From "The Pink Sheet" DAILY - Sanofi In Diabetes Pact With Metabolex

Sanofi-Aventis Takes Rights to Metabolex's Diabetes Compound

As it continues to diversify away from its juggernaut Lantus, Sanofi takes a chance on a potential first-in-class drug not yet through Phase II.   read more

Coming in Monday's "The Pink Sheet" DAILY - Sanofi Inks Deal For Phase II Diabetes Drug

A technical fix to language defining average manufacturer price for drugs would cost pharma firms $2.1 billion over 10 years, the Congressional Budget Office says.